Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukos

Ripple Therapeutics announced a new evaluation and licensing agreement with Glaukos this week that aims to leverage Ripple’s patented technology platform to create sustained release implants of targeted therapeutics for both glaucoma and retinal diseases.

Financial terms of the deal were not disclosed.

"This is the first of what we believe will be a number of transactions using our technology platform in concert with partners' APIs to create sustained release implants which will benefit patients with extended duration and improved safety,” said Tom Reeves, President & CEO of Ripple Therapeutics, in a press release.

Ripple’s technology platform is based on the principle that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers or excipients; these prodrugs are highly engineerable to tailor both drug dose and duration. The company claims this technology allows their therapeutics to have lower molecular weight and higher drug loading, allowing for smaller implants and overall better safety profiles. According to Ripple, if the program with Glaukos is successful, the evaluation agreement will automatically convert into a licensing agreement.

“We believe Ripple has one of the most promising drug delivery technologies currently under development,” said Tomas Navratil, PhD, Chief Development Officer of Glaukos. "We are pleased with the progress of our collaboration and have enjoyed working with the Ripple team as we work together to bring these much-needed sustained release products to patients with critical unmet needs."